TTK and melanoma: Nowadays, five small molecule inhibitors of TTK are currently under clinical study for head and neck, endocrine, gastrointestinal, genitourinary, gynecologic, and breast cancers, as well as melanomas and sarcomas of the soft tissue and bone [61–65].